关于先锋

Company Profile

Start a strong alliance and create a better future hand in hand!


On January 7, 2021, Anhui Pioneer Pharmaceutical Co., Ltd. and Hangzhou Zhongmei Huadong Pharmaceutical officially signed a strategic cooperation agreement, reaching a strategic partnership for Guipi Capsules in the national clinical, OTC and three-terminal markets. In terms of market promotion of Guipi Capsules, carry out all-round and in-depth strategic cooperation, join forces and advance hand in hand, so as to promote the rapid development of the Baisi Ning® Guipi Capsules invigorating the spleen and calming the nerves market.

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of the listed company Huadong Medicine Co., Ltd. (stock code: 000963). It has a strong sales network and rich clinical channels, and has successfully created many well-known product brands such as Bailing Capsules. .

5 Ranked No. 1 for 5 years in the product share of similar Guipi preparations

Anhui Pioneer Pharmaceutical Co., Ltd. is a comprehensive national high-tech enterprise integrating production, sales and scientific research. The company was established in January 2004. It is located in the center of the national high-tech zone and has domestic advanced freeze-dried powder injections. , cephalosporin powder injection, capsule, tablet, granule, external solution, traditional Chinese medicine extraction and other production lines. The products cover cardiovascular, respiratory, antibacterial and anti-inflammatory and other therapeutic fields. The company's products have also established a good market reputation. The company's leading product, Guipi Capsules, is widely recognized by the market, and its market network covers the whole country. Since 2018, it has ranked first in the market share of similar Guipi preparations for five consecutive years.

Under the general environment of national pharmaceutical market structural adjustment, our company has continuously strengthened its research and development capabilities, innovated marketing models, explored new channels for the market, and reached a number of strategic partnerships in sales and research and development, pushing the company into a benign development track. The conclusion of this strategic cooperation will give full play to the advantages of Pioneer Pharmaceutical products and Sino-US Huadong Pharmaceutical channels, and join hands to create a brilliant future together!

R & D cooperation

Anhui Pioneer Pharmaceutical Co., Ltd. (referred to as "Pioneer Pharmaceutical") and Changsha Duzheng Biotechnology Co., Ltd. (referred to as "Duzheng Bio") formally signed a strategic cooperation agreement. Chen Zhenghao, Chairman of Pioneer Pharmaceuticals, Quan Chunming, Manager of R&D Department, Ouyang Dongsheng, Chairman/President of Duzheng Bio, Li Xiaohui, Vice President and other leaders attended the signing ceremony.

Ouyang Dongsheng said that the best cooperation between enterprises is to enable both parties to develop together. Pioneer Pharmaceuticals is developing rapidly and has great prospects. Duzheng Biotech is full of confidence and expectations for the cooperation between the two parties. In the future, Duzheng Biotech will provide high-level technical services for Pioneer Pharmaceuticals, and the two parties will work together to help the industry develop.

Chen Zhenghao fully affirmed the development potential and technical level of Duzheng Biotechnology. He pointed out that this cooperation is based on a highly consistent strategic consensus between the two parties, and the advantages of the companies complement each other. In the future, we will jointly innovate the industry and create a new direction for development!


Copyright © 2023 Hypuron  Powered by:www.300.cn   SEO

Business License

公司简介


安徽省先锋制药有限公司是一家集生产、销售、科研于一体的综合型国家高新技术企业,企业成立于2004年1月,注册资本2000万元,位于国家级高新区的中心地带,占地30余亩,建筑面积30000㎡。企业建有国内先进的冻干粉针剂、头孢粉针剂、胶囊剂、片剂、颗粒剂、外用溶液剂、中药提取等多条生产线,产品覆盖心血管、呼吸、抗菌消炎等多个治疗领域。

公司拥有职工300余人,本科及以上学历占比达40%;技术中心专职研发人员38人,执业药师8人;企业自成立以来,累计纳税近3亿元,企业勇于承担社会责任,解决本地就业问题,为本地税收做出较大贡献。公司先后通过“国家级高新技术企业”、“合肥市亩均贡献A类企业”、“安徽省专精特新中小企业”、“高新区瞪羚企业”、“安徽省企业技术中心”“合肥市工程研究中心(合肥市新盐型药物工程研究中心)”、“安徽省三重一创高新技术企业增长补助”、“合肥市三重一创高新技术企业增长补助”、“合肥高新区三重一创补助”、“合肥市企业技术中心”、“深科技企业”、“安徽省皖美品牌企业”等荣誉认证。

2015年公司在上海张江高科建立了现代化的研究所上海皓锋医药科技有限公司,依托张江国家开发区的地域及资源优势,为公司源源不断的注入新的活力。公司整合上海皓锋研发基地和合肥总部研发中心资源,建立了安徽省企业技术中心,构建了较为完善的以企业为主体,产、学、研、用相结合的技术创新体系,与安徽中医药大学、上海交通大学、安徽省农业大学等高校开展多种形式研发合作。

在全国医药市场结构调整的大环境下,我公司不断加强研发力量、创新营销模式、探索市场开拓新渠道,公司进入了一种良性的发展轨道。公司产品也建立了良好市场口碑,公司主导产品注射用盐酸克林霉素、注射用克林霉素磷酸酯、归脾胶囊和甘草酸二铵肠溶片等被市场所认可,市场覆盖全国近30个省份。其中皓瑞®注射用盐酸克林霉素、百思宁®归脾胶囊自2018年以来,连续5年占同类产品市场份额排名第一。

2023年安徽省先锋制药正式启动上市计划,计划2026年企业在北交所和创业板上市挂牌,企业第一个五年计划结束后,将迎来企业展翅腾飞、焕发新生的美好未来!